Hello Investing Friend!!
I hope you are well!!
If not, I have a special report for you on a biotech stock with a sneaky near-term catalyst for a big buyout!!
And I have some options plays for you as well.
We have been saying that long-suffering biotech could be on the verge of a golden age.
Goodness knows it has been a long hard slog:
And check this healthcare misery out (these are median returns, not mean):
But now in the last month, the biotech sector has perked up a bit.
And the mergers and acquisitions environment is heating up, too. Most recently with Blueprint Medicines fetching a four to five times peak sales multiple from Sanofi:
And:
So today we have a biotech stock that is a buy in its own right.
But it also has a special, subtle, and powerful catalyst to get bought out for a big premium in the next seven weeks.
The catalyst has a bit to do with the President’s executive order on the equalization of drug prices globally:
The stock is…